Intellia Therapeutics (NTLA) Stock
Clinical stage biotech developing gene editing therapies for diseases. Here's the price, business snapshot, and what's worth knowing about Intellia Therapeutics in August 2026.
Intellia Therapeutics (NTLA) is a clinical-stage biotechnology company developing CRISPR/Cas9-based gene‑editing therapies. It is pursuing both in vivo and ex vivo approaches targeting genetic and liver diseases, with a pipeline of early clinical and preclinical programmes. Investors should understand that Intellia’s potential rests on demonstrating safe, durable benefits in human trials — a process that can take years and is subject to clinical, regulatory and competitive risk. With a market capitalisation near $2.9bn, the company’s valuation is sensitive to trial readouts, partnership deals and financing activity. Research and development spending is substantial and outcomes are uncertain, so share price volatility is common. This summary is educational only and not personalised financial advice; investors should consider their time horizon, risk tolerance and diversification needs before considering exposure to NTLA.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Intellia Therapeutics' stock with a target price of $40.5, indicating strong potential growth.
Financial Health
Intellia Therapeutics is generating moderate revenue and cash flow, but its financial position is stable.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
CRISPR Therapy Pipeline
Early clinical readouts could materially affect valuation, though trials can fail and timelines often slip.
Clinical Catalysts Ahead
Trial milestones, regulatory updates and partnerships tend to move the stock; outcomes remain binary and uncertain.
Long‑term Potential
Successful programmes could change care for some diseases, but benefits are speculative and carry substantial scientific and commercial risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
